Reprint

Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach

Edited by
June 2023
316 pages
  • ISBN978-3-0365-7881-1 (Hardback)
  • ISBN978-3-0365-7880-4 (PDF)

This book is a reprint of the Special Issue Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Although DNA repair enzymes play a crucial role in maintaining the integrity of the genome, the hyperactivity of certain enzymes of the DNA repair system can lead to the resistance of tumors to chemo- and radiotherapy, aimed at damaging the DNA of cancer cells. Therefore, the inhibition of DNA repair enzymes could help to overcome this resistance. The reviews and research articles included in this collection describe the molecular mechanisms of action of some important enzymes of the DNA repair system, as well as some new inhibitors of such enzymes and the pharmacological properties of these inhibitors. This reprint clearly demonstrates the importance of the inhibition of DNA repair enzymes to fight various diseases, especially cancer.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
poly (ADP-ribose) polymerase inhibitor; non-small cell lung cancer; DNA damage; radiotherapy; chemotherapy; combination therapy; coumarin; neoflavone; DNA repair enzymes; Tdp1 inhibitor; cancer; tumor; topotecan; topoisomerase 1 inhibitors; molecular modeling; chemical space; morpholino nucleosides; molecular modeling; NAD+ analogs; DNA repair; PARP; 7-methylguanine; poly(ADP-ribose) polymerase 1; inhibitor; nucleosome; trapping; docking; molecular dynamics; fluorescence anisotropy; spFRET microscopy; DNA repair; DNA glycosylases; drug targets; APE1; protein–protein interactions; base excision repair; multifunctional disordered protein; fluorescence techniques; cell cycle checkpoint; DNA repair; cancer therapy; DNA repair inhibitors; synthetic lethality; fused in sarcoma; DNA repair; poly(ADP-ribose) polymerase; poly(ADP-ribose); protein phase separation; berberine; tetrahydroberberine; Tdp1 inhibitor; cancer; molecular modeling; DNA repair enzyme; SAR; poly(ADP-ribosylation); PARP-1; Olaparib; KU55933; KU-0060648; SCR7 pyrazine; VERO cells; synergism; resistance; CDKN2A; soft tissue sarcomas (STS); gastrointestinal stromal tumors (GIST); AKT signaling; Rad51 recombinase; homology-mediated DNA repair; apoptosis; sensitization; DNA damage; chemotherapy; XPA; ERCC1-XPF; CSB; UVB radiation; UVB mutagenesis; nucleotide excision repair (NER); cyclobutane–pyrimidine dimer (CPD) photolesion; veliparib; resveratrol; arsenic trioxide; spironolactone; usnic acid; thioether; tyrosyl-DNA phosphodiesterase 1; TDP1 inhibitor; inhibiting activity; TDP2; PARP1; topotecan; synergy; HEK293 knockout cell line; PARP-1; polyphenols; PARP-1 inhibitors; n/a